N-acetylcysteine, ascorbate

PreclinicalSmall molecule

N-acetylcysteine, ascorbate is one of 7 small molecule programs targeting Endothelial Function. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial FunctionCompleted

Endothelial FunctionPreclinical

Completed

Competition

Competitive Landscape

8 competitors in Endothelial Function

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

1 2

Nulojix

Bristol-Myers Squibb

Approved

1 3

Azulfidine

Pfizer

Preclinical

1 4

Slow Sodium

SSt George's, University of London

Preclinical

2 5

Viagra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

N-acetylcysteine, ascorbate

UUniversity of Washington

Preclinical

1 7

L-NG-Monomethyl Arginine (l-NMMA)

EEmory University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endothelial Function1 trial

Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans

Completed·UUniversity of Washington·N/A·NCT00434005·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for N-acetylcysteine, ascorbate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-acetylcysteine, ascorbate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-acetylcysteine, ascorbate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Washington

N-acetylcysteine, ascorbate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endothelial Function1 trial

References

Drug Info

Quick Facts

Related News